The U.S. Food and Drug Administration (FDA) has officially approved avobenzone and octocrylene-based sunscreen formulations containing bemotrizinol, marking the first new active sunscreen ingredient authorized in the United States in over two decades. This decision, finalized in May 2024, allows for the use of the UV filter already common in Europe and Asia, potentially addressing long-standing consumer demand for more modern, stable sun protection products.
Why did the FDA approve this ingredient now?
The FDA approval follows the implementation of the Over-the-Counter Monograph Safety, Innovation, and Reform Act (OMUFA), which modernized the agency’s process for reviewing non-prescription drugs. According to the FDA’s official regulatory filings, the agency determined that the ingredient meets the necessary safety and efficacy standards for broad-spectrum UV protection.
For years, the U.S. market lagged behind international standards because the FDA classified sunscreens as drugs, requiring a rigorous and lengthy clinical trial process for new filters. The new regulatory pathway allows for a more streamlined assessment of ingredients that have already demonstrated safety in other major global markets.
What is bemotrizinol and how does it differ?
Bemotrizinol, also known by its trade name Tinosorb S, is a broad-spectrum, oil-soluble UV filter. Unlike many older ingredients currently used in U.S. sunscreens, it is highly photostable, meaning it does not break down quickly when exposed to sunlight.
| Feature | Older UV Filters (e.g., Avobenzone) | Bemotrizinol |
|---|---|---|
| Photostability | Often degrades under UV light | High; remains stable |
| Broad Spectrum | Usually requires stabilization | Inherently broad-spectrum |
| Global Availability | Limited to specific markets | Used globally for decades |
As noted by the American Academy of Dermatology, the addition of more stable filters can lead to sunscreens that are less irritating to the skin and provide longer-lasting protection, as they do not require as many stabilizing additives.
What happens next for consumers?
While the FDA has cleared the path for the use of this ingredient, it will not appear on store shelves immediately. Manufacturers must now undergo the standard formulation and stability testing required for any new OTC drug product. According to the Consumer Healthcare Products Association, companies are currently reviewing the agency’s specific requirements to determine the timeline for integrating the filter into their product lines.
Experts anticipate that the inclusion of this ingredient will eventually allow American consumers to access the same high-performance sunscreens that travelers have purchased in pharmacies across Europe and Asia for years.
Frequently Asked Questions
Is this the only new ingredient approved?
No, this approval is part of a broader effort by the FDA to update the monograph for sunscreen drug products to reflect modern chemical advancements.
Is bemotrizinol safer than current ingredients?
The FDA’s approval is based on extensive clinical data indicating that the ingredient is safe for topical use, consistent with its long-term safety profile in international markets.
When will I see this in my local pharmacy?
There is no set date for the first product launch. Manufacturers must first submit their specific formulations to the FDA for review, which typically takes several months of testing and documentation.